Detalhe da pesquisa
1.
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Haematologica
; 109(3): 867-876, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646657
2.
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Br J Haematol
; 193(6): 1105-1109, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33403663